Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic Hyperplasia

European Urology

Volumn 44, Issue 6, 2003, Pages 695-700

  Mochtar, C A ^a   Kiemeney, L A L M ^b   Van Riemsdijk, M M ^c   Barnett, G S ^d   Laguna, M P ^a   Debruyne, F M J ^b   De La Rosette, J J M C H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GLAXOSMITHKLINE   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Prostate volume; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SYMPTOMATOLOGY;

EID: 0346275131     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00384-1     Document Type: Article

References (25)

1. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581-9.
2. Morote J, Encabo G, Lopez M, de Torres IM. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 2000;38:91-5.
3. Kane RA, Littrup PJ, Babaian R, Drago JR, Lee F, Chesley A, et al. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992;69(5): 1201-7.
4. Babaian RJ, Miyashita H, Evans RB, Ramirez EI. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 1992;147(3 Pt 2):837-40.
5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270(7):860-4.
6. Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M. Realtionship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993;71:445-50.
7. Bosch JLHR, Hop WCJ, Bangma CH, Kirkels WJ, Schroder FH. Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate 1995;27: 241-9.
8. Di Silverio F, Sciarra A, D'Eramo G, Casale P, Loreto A, Seccareccia F. Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases. Prostate 1998;36:1-7.
9. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al., for the PLESS Study Group. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163:13-20.
10. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996:48(3): 398-405.
11. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51(5): 677-86.
12. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types I and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41.
13. Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs 1999;57(4):557-81.
14. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002;167(4):1734-9.
15. Mimata H, Satoh F, Ohno H, Miyoshi M, Nomura Y. Clinical characteristics of alpha-blocker responders in men with benign prostatic hyperplasia. Urol Int 2002;68(4):237-42.
16. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58(5):717-22.
17. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998;160(4):1358-67.
18. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158(2):481-7.
19. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al., for the PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473-80.
20. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001;57(6):1087-92.
21. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991;179(1): 49-53.
22. Roehrborn CG, Chinn HK, Fulgham PF, Simpkins KL, Peters PC. The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy. J Urol 1986;135(6): 1190-3.
23. Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000;38:2-19.
24. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338(9):557-63.
25. Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38(5):563-8.